Ötzi the Iceman and his neighbors had totally different ancestries, ancient DNA study finds
A new analysis of ancient DNA from 15 people who lived in the Italian Alps around the same time as Ötzi the Iceman shows that Ötzi's ancestry was decidedly different from his neighbors'.
"We analysed an additional 15 Copper Age individuals and they have the same genetic structure as the Iceman," Valentina Coia, a researcher at the Institute for Mummy Studies in Bolzano, Italy, told Live Science in an email. But when looking more closely at the DNA to understand lineages, "we were able to compare the results with those of the Iceman and found that it differs from the other Alpine samples in the area."
In a study published July 11 in the journal Nature Communications, Coia and colleagues analyzed the genomes of 47 people who lived in the Tyrolean Alps between the Mesolithic and the Middle Bronze Age, around 6400 to 1300 B.C., to learn more about their ancestry.
The most famous individual they examined was Ötzi, who lived 5,300 years ago in the Alps before he was murdered in mysterious circumstances. His mummified and frozen corpse was discovered by tourists in 1991. Because a previous study found that Ötzi had "unusually high Anatolian farmer ancestry," the researchers wanted to investigate whether the Iceman's neighbors — who lived in the Alps in the Copper Age, between 3368 and 3108 B.C. — had a similar ancestry or whether they were more closely related to hunter-gatherer groups from the Eurasian Steppe.
The researchers' analysis of the ancient genomes revealed that most prehistoric Alpine people had high proportions of Anatolian farmer ancestry (80% to 90%) and low proportions of hunter-gatherer ancestry. Most of these people also displayed a similar genomic structure and ancestry, they wrote in the study.
For example, the Y-chromosome data, which helps trace paternal lineage, revealed that nearly all males who were tested shared a similar ancestry that has been found in prehistoric Germany and France. Ötzi, by contrast, had a different paternal lineage that was more widespread, the researchers wrote.
Related: Ötzi the Iceman used surprisingly modern technique for his tattoos 5,300 years ago, study suggests
While the paternal lineages of the prehistoric Alpine men were broadly similar, their maternal lineages were diverse, suggesting that women may have been marrying into a close-knit group of men.
But Ötzi's maternal lineage has never been identified in other ancient or modern individuals, the researchers wrote, and it was not found in any of the other Alpine people analyzed in the study.
"As the maternal line has never yet been found, this might suggest its extinction," Coia said. But she cautioned that the data are somewhat difficult to interpret.
"Perhaps the Iceman, compared to other individuals of the same period, comes from a different group of farmers, but this can only be discovered if we have more data on Neolithic individuals from Anatolia and northern Italy," she said.
Because a previous study had revealed Ötzi had dark hair and dark eyes, the researchers also looked for these traits in six individuals whose genomes were complete enough to predict hair and eye color. "These [people] likely had brown eyes associated with dark brown to black hair colour (similarly to the Iceman)," they wrote. And their genomes also revealed that all of the prehistoric Alpine people were lactose intolerant, as was Ötzi.
RELATED STORIES
—Ötzi the Iceman's mummified corpse was found in an Alpine gully — but he didn't die there, new study finds
—Ötzi the Iceman may have scaled ice-free Alps
—7 famous mummies and secrets they've revealed about the ancient world
Prior to this study, only two genomes of Copper Age people from the eastern Italian Alps had been analyzed. The additional 15 new genomes from Ötzi's "neighbors" are improving the researchers' understanding of the lives of people who lived in this cold, high-altitude region.
"We have no information on the cultural group to which the Iceman may have belonged," the researchers wrote, so "our findings leave open some questions about the genetic origin and cultural affiliation of this enigmatic individual."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a point-of-care diagnostics company, today announces the appointments of Bob Yang as Chief Medical Officer (CMO), Maddy Kennedy as Chief Financial Officer (CFO), and Mark Preston as Chief Technology Officer (CTO). These strategic appointments strengthen Llusern's leadership team as the company builds on its recent ISO 13485 certification and progresses towards IVDR certification, positioning Lodestar DX for upcoming commercial launches across Europe for treatment-directing diagnosis of urinary tract infections (UTIs). Bob Yang joins Llusern Scientific as Chief Medical Officer. A highly accomplished urology consultant, Mr. Yang brings extensive expertise in complex and recurrent UTIs and male and female incontinence. He has made significant contributions to antibiotic-free treatment options for recurrent UTIs and has been pioneering research in sub-lingual UTI vaccines and male incontinence devices. His expertise will directly complement Llusern's mission to revolutionize UTI diagnostics and support antimicrobial stewardship through the Lodestar DX system, a rapid diagnostic platform designed to enhance clinical decision-making. He is Lead Editor for Springer Nature academic textbooks on Urinary Tract Infections and Male Incontinence, solidifying his standing as one of the global leaders in urological research and practice. Mr. Yang continues to pioneer in his field as a urology consultant at the Royal Berkshire NHS Foundation Hospital and an Associate Lecturer at Oxford University. 'Joining Llusern Scientific is an exciting opportunity to contribute to the growth of innovative diagnostic solutions that will improve patient outcomes globally,' said Bob Yang, Chief Medical Officer of Llusern Scientific. 'The Lodestar DX system offers clinicians a powerful tool to make precise treatment decisions in a single visit, thereby enabling them to combat antimicrobial resistance through improved antibiotic stewardship.' As Chief Financial Officer, Maddy Kennedy brings over 25 years of experience in financial strategy, investor relations, and corporate governance to Llusern Scientific. She will play a crucial role in supporting Llusern's fundraising activities and steering its expansion into global markets. Known for her ability to translate complex development programs into clear financial plans, Maddy has successfully guided life sciences and technology businesses through strategic growth, M&A, IPOs, and exit planning. Her leadership roles at companies such as Maxwellia, Kesmalea Therapeutics, and Psioxus Therapeutics have equipped her with expertise in scaling operations and securing funding. She brings strong governance expertise from Non-Executive Director roles at Nuformix plc, Heartbeat CIC, and Tetris Pharma. She is currently also CFO at PBD Biotech and Fermtech. 'I am excited to join Llusern Scientific at this crucial stage of its development,' said Maddy Kennedy, Chief Financial Officer of Llusern Scientific. 'With its innovative Lodestar DX system poised for expansion into new markets, I look forward to supporting Llusern's growth and overseeing the financial operations needed to achieve its global ambitions.' Mark Preston joins Llusern Scientific as Chief Technology Officer, bringing extensive expertise in biotech, data analytics, and cloud technologies. As CTO, Mark will lead the development of Lodestar DX overseeing technological innovation, scalability, and compliance. Mark's early career includes experience in embedded systems and devices at Sony and Panasonic, working on networking hardware, mobile phones, and microscopes. His later work in app development, AI-driven insights, and workflow optimization enabled him to deliver scalable, secure, and compliant solutions for start-ups and global organizations, including vaccine manufacturers. As a Founder and Managing Director of consultancy firm Prismea, Mark helps biotech companies innovate with data analytics, cloud systems, and regulatory compliance as well as navigating medical regulatory frameworks with organizations such as the MHRA. 'I've been impressed by the Lodestar DX system and its ability to deliver treatment directing diagnosis of UTIs at the point of care,' said Mark Preston, Chief Technology Officer. 'I look forward to supporting the company's efforts to bring precision diagnostics to healthcare settings worldwide.' Emma Hayhurst, Co-founder and CEO of Llusern Scientific, commented:'We are thrilled to welcome Bob, Maddy, and Mark to our executive leadership team. Their deep expertise in urology, finance, and technology will be instrumental in ensuring Llusern remains at the forefront of providing precise, accessible diagnostic solutions that deliver improved outcomes for patients suffering from UTIs.' Notes to Editors About Llusern ScientificLlusern Scientific is a treatment-directing molecular diagnostics company, developing fast, accurate, and accessible tools to guide real-time clinical decision-making at the point-of-care. Our flagship solution, Lodestar DX, is a portable diagnostic device that delivers lab-accurate results for urinary tract infections (UTIs) in around half an hour. It is based on isothermal LAMP technology (not PCR) without the need for DNA extraction or centralized lab infrastructure. With industry-leading sensitivity and specificity, Lodestar DX empowers clinicians to diagnose and treat specific microbial infections with precision in a single visit, thereby improving patient outcomes. As well as providing guidance on the best treatment option based on the specific microbial infection, Lodestar DX also provides a clear 'rule-out' decision where antibiotics are not necessary, helping to reduce antimicrobial resistance through antibiotic stewardship. Building on success in the UK, Llusern is preparing for commercial launches across India and the MENA region in 2025 and the US in 2026. Llusern is committed to transforming diagnostic pathways and making precision medicine equitable, portable, and fast. Due to its small size and ease of portability Lodestar DX is particularly suitable for resource limited and decentralised healthcare settings including care homes, mobile diagnostics, and community diagnostic centres. Additionally Lodestar DX has uses within paediatrics, urology, and other secondary care settings. The Lodestar DX UTI testing system has been independently evaluated in studies by University of Oxford, Norfolk and Norwich University Hospital, Southampton University, and Public Health Wales. The company was established in 2020 as a spin-out from the University of South Wales, UK. For more information, visit and follow us on LinkedIn. Media Contacts Llusern ScientificMartyn Lewis +44 (0) 7825 708936martyn@ Scius CommunicationsKatja Stout +44 (0) 7789435990katja@ Daniel Gooch +44 (0) 7747875479daniel@ in to access your portfolio


Medscape
2 hours ago
- Medscape
QoL Deserves More Than a Footnote in Cancer Trials
In a review published in New England Journal of Medicine Evidence , Massimo Di Maio, MD, from the Department of Oncology at the University of Turin in Turin, Italy, and president-elect of the Italian Association of Medical Oncology, offers a detailed analysis of how patient-reported outcomes are used in clinical trials and explains the best practices for interpreting quality-of-life (QoL) data. 'QoL data are increasingly being included in oncology trials,' Di Maio told Univadis Italy, a Medscape Network platform. 'However, the scientific community is less familiar with interpreting — or critically assessing — this type of data compared with more traditional endpoints like progression-free survival or overall survival.' With growing support from scientific societies and regulatory agencies, QoL has become a standard endpoint in many studies. Yet practical guidance on its interpretation remains limited. Di Maio, who also served as lead author of the European Society For Medical Oncology guidelines on the use of patient-reported outcome measures in oncology, views this as a significant gap in the field. 'We must not forget that for many patients — especially those in advanced stages of disease — living well can be just as important, if not more so, than living longer,' he emphasized. He also cautioned that statistical significance does not always translate into meaningful clinical benefit. From Trial Design... To accurately assess QoL and maximize the value of the data, clinical trials must be appropriately designed from the outset. As outlined in the article, phase 3 randomized trials offer the ideal framework for QoL measurement. They allow investigators to compare results between treatment and control groups, tracking changes from baseline and over time. Di Maio explains in the review that randomized trial designs help ensure that any differences observed between study arms are directly linked to the treatment itself. Speaking with Univadis Italy , he also addressed the potential for bias in QoL data collection. 'Some researchers argue that simply knowing they are receiving the experimental treatment may lead patients — perhaps even subconsciously — to perceive a benefit, which could influence patient-reported outcomes like QoL,' he said. Still, Di Maio noted the difficulty in rigorously proving the existence or magnitude of such bias. Ideally, this would be tested by comparing blinded and open-label trials, but these studies are uncommon and logistically challenging. One coordinated analysis, led by Fabio Efficace, PhD, of the Italian Group for Adult Hematologic Diseases, found that trial blinding was not an independent predictor of QoL benefit. While the potential for bias cannot be dismissed, Di Maio believes its real-world impact is likely modest — and that open-label studies can still yield valid and meaningful QoL data. ...To Data Interpretation Few oncology trials designate QoL as a primary endpoint, but this isn't inherently a limitation, Di Maio noted. QoL can still be a valuable secondary endpoint — provided the results are interpreted carefully and in the proper context. One of the central challenges is patient compliance with QoL questionnaires, which tends to be inconsistent. Factors contributing to low completion rates include limited time for clinicians to communicate the importance of QoL data, patient dropout due to disease progression or adverse outcomes, and technical issues such as failures in electronic data capture or patients' unfamiliarity with digital tools. In such cases, Di Maio suggested that having a paper-based backup system can improve data reliability. Ultimately, QoL should not be viewed as an optional or secondary concern, but as a fundamental part of assessing the true value of cancer therapies. Patient-reported outcome measures, while designed to capture quality of life, also offer critical insights into the broader effectiveness and utility of treatments. 'QoL data alone aren't sufficient,' Di Maio emphasized, 'but they are indispensable for understanding the value of a therapy — and for communicating that value clearly to patients.' He concluded that interpreting QoL data accurately is not just a scientific imperative but also an ethical obligation to patients navigating serious and often life-limiting conditions.
Yahoo
2 hours ago
- Yahoo
Parkinson's Disease Has a Smell That Some Dogs Can Detect
Dogs really can be trained to smell Parkinson's disease, according to new research from the United Kingdom. In a double blind trial, a Golden Retriever and a Labrador were able to sniff out which skin swabs came from people with Parkinson's. The smell of the oily secretions seemed to hold secret clues. "The dogs in this study achieved high sensitivity and specificity and showed there is an olfactory signature distinct to patients with the disease," says animal behavioral scientist Nicola Rooney from the University of Bristol. "Sensitivity levels of 70 percent and 80 percent are well above chance, and I believe that dogs could help us to develop a quick, non-invasive, and cost-effective method to identify patients with Parkinson's disease." Related: Today, there is no definitive early test for Parkinson's, which is why scientists are so interested in finding potential biomarkers of the disease on our skin. The knowledge that Parkinson's distinctly changes a person's body odor first came to light roughly a decade ago – all because of one woman. Twelve years before her husband's diagnosis of Parkinson's disease, Joy Milne could sense something was off – specifically, she could smell it. Milne, a Scottish nurse, is known as a 'super-smeller', and in 2016, she became famous among neuroscientists for her extraordinary abilities. In a small pilot study, Milne correctly identified each patient with Parkinson's disease based solely on the scent of their shirts. Her one misidentification turned out to be correct nearly a year later. The news raised an important question: If someone like Milne could smell Parkinson's years before it was diagnosed, could a dog do the same? Dogs are known to have incredible senses of smell, far more powerful than our own. Previous studies have found our pets can smell our stress, our coronavirus infections, and even our cancers – so if a distinct odor for Parkinson's does exist, then maybe a dog can sniff it out, too. In the past decade, a few preliminary trials have provided evidence for that hypothesis. But some only gave limited information on how the dogs were trained and tested. The recent trial from the UK is a collaboration between a program called Medical Detection Dogs and neuroscientists at the University of Manchester. One goal of the research is to figure out what the dogs are actually smelling, and why. In 2019, for instance, researchers at Manchester helped identify which odor compounds set the distinctive smell of Parkinson's apart. Their results were later confirmed by Milne, the serendipitous "super-smeller". A few years on, the odor compounds were used to create a diagnostic 'swab test' for Parkinson's, currently in testing. Perhaps, further down the road, trained dogs could help neuroscientists identify more unique biomarkers of the disease. The trouble is, though, not all canines are up to snuff. In the current trial, only 2 out of 10 dogs made it through training, and neither performed perfectly. One dog, for instance, falsely flagged a tenth of the odor swabs from healthy people as having Parkinson's. The other gave false alarms less than 2 percent of the time. Overall, however, the dogs could smell which person had Parkinson's at a rate well above chance, providing proof of principle. "We are extremely proud to say that once again, dogs can very accurately detect disease," says Claire Guest, the CEO of Medical Detection Dogs. "There is currently no early test for Parkinson's disease and symptoms may start up to 20 years before they become visible and persistent leading to a confirmed diagnosis. "Timely diagnosis is key… " The study was published in the Journal of Parkinson's Disease. Related News Expert Reveals What Can Happen if Testosterone Gel Rubs Onto Others Radioactive Waste Exposed Children in Missouri to Cancer Risks, Study Finds A Single Brain Scan Halfway Through Your Life Can Reveal How Fast You're Aging Solve the daily Crossword